Mural Oncology plc (MURA)
NASDAQ: MURA · IEX Real-Time Price · USD
3.780
-0.020 (-0.53%)
May 10, 2024, 4:00 PM EDT - Market closed
Company Description
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer.
The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs.
Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Mural Oncology plc
| Country | Ireland |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 117 |
| CEO | Ms. Caroline J. Loew Ph.D. |
Contact Details
Address: 10 Earlsfort Terrace Dublin 2, L2 D02 T380 Ireland | |
| Phone | 353 1 905 8020 |
| Website | muraloncology.com |
Stock Details
| Ticker Symbol | MURA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001971543 |
| ISIN Number | IE000LK2BOB4 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Caroline J. Loew Ph.D. | Chief Executive Officer and Director |
| Adam D. Cutler B.A. | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Maiken Keson-Brookes | Chief Legal Officer |
| Justin Levine | Head of Human Resources and Vice President of Human Resources |
| Dr. Vicki L. Goodman M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 12, 2024 | ARS | Filing |
| Apr 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 12, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 26, 2024 | 10-K | Annual Report |
| Mar 26, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 2, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |